Literature DB >> 16595564

Life expectancy in patients with hereditary haemorrhagic telangiectasia.

C Sabbà1, G Pasculli, P Suppressa, F D'Ovidio, G Mariano Lenato, F Resta, G Assennato, G Guanti.   

Abstract

BACKGROUND: There are few data on life expectancy in patients with hereditary haemorrhagic telangiectasia (HHT), a disorder with life-threatening complications.
METHODS: Seventy HHT patients provided data on age and age at death of their HHT-affected parent, which was compared with that of the parent's non-affected partner.
RESULTS: At the time of the study, 40 HHT parents (57.1%) vs. 36 (51.4%) non-HHT parents had died (p = 0.404). Median age at death was lower in HHT vs. non-HHT parents (63.2 vs. 70.0 years, respectively). The mortality of HHT parents showed an early peak in the under 50s and a late peak at 60-79 years. HHT was the main risk factor influencing life expectancy after 30 years (p < 0.05). No differences in survival probability were found in HHT patients with respect to sex (p = 0.37), or ENG vs. ALK-1 genotype (p < 0.9). DISCUSSION: Life expectancy appears to be significantly lower in HHT patients than in their partners. Prevention of HHT complications with screening programs could increase life expectancy.

Entities:  

Mesh:

Year:  2006        PMID: 16595564     DOI: 10.1093/qjmed/hcl037

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  24 in total

Review 1.  Embolisation for pulmonary arteriovenous malformation.

Authors:  Charlie C-T Hsu; Gigi Nc Kwan; Hannah Evans-Barns; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2018-01-04

2.  The Subjective Experience of Patients Diagnosed with Hereditary Hemorrhagic Telangiectasia: a Qualitative Study.

Authors:  Laura Geerts; Carole Fantini-Hauwel; Elodie Brugallé; Odile Boute; Frédéric Frénois; Lydie Defrance; Sylvie Manouvrier-Hanu; Florence Petit; Pascal Antoine
Journal:  J Genet Couns       Date:  2016-10-28       Impact factor: 2.537

Review 3.  Gastrointestinal Manifestations of Hereditary Hemorrhagic Telangiectasia (HHT): A Systematic Review of the Literature.

Authors:  Samuel B Jackson; Nicholas P Villano; Jihane N Benhammou; Michael Lewis; Joseph R Pisegna; David Padua
Journal:  Dig Dis Sci       Date:  2017-08-23       Impact factor: 3.199

4.  Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study.

Authors:  James W Donaldson; Tricia M McKeever; Ian P Hall; Richard B Hubbard; Andrew W Fogarty
Journal:  Neurology       Date:  2015-04-10       Impact factor: 9.910

5.  Recurrent erysipelas led to diagnosis of hereditary hemorrhagic telangiectasia.

Authors:  Mari Yamaoka; Yohei Kanzawa; Shun Tatehara; Koji Sasaki; Shimpei Mizuki; Jun Ohnishi; Takahiro Nakajima; Naoto Ishimaru; Saori Kinami
Journal:  Infez Med       Date:  2022-03-01

6.  Small bowel adenocarcinoma arising in a patient with hereditary hemorrhagic telangiectasia: A case report.

Authors:  Yuichiro Yoshioka; Hiroaki Nozawa; Junichiro Tanaka; Takeshi Nishikawa; Toshiaki Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Keisuke Hata; Shinsuke Kazama; Hironori Yamaguchi; Soichiro Ishihara; Eiji Sunami; Joji Kitayama; Toshiaki Watanabe
Journal:  Oncol Lett       Date:  2016-02-01       Impact factor: 2.967

7.  Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia.

Authors:  Barbara A Bernhardt; Cara Zayac; Reed E Pyeritz
Journal:  Genet Med       Date:  2011-09       Impact factor: 8.822

8.  Restless Leg Syndrome Is Underdiagnosed in Hereditary Hemorrhagic Telangiectasia-Results of an Online Survey.

Authors:  Freya Droege; Andreas Stang; Kruthika Thangavelu; Carolin Lueb; Stephan Lang; Michael Xydakis; Urban Geisthoff
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

9.  Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls.

Authors:  Anna E Hosman; Hannah L Devlin; B Maneesha Silva; Claire L Shovlin
Journal:  Orphanet J Rare Dis       Date:  2013-12-20       Impact factor: 4.123

10.  The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia.

Authors:  Scott D Grosse; Sheree L Boulet; Althea M Grant; Mary M Hulihan; Marie E Faughnan
Journal:  Genet Med       Date:  2013-05-23       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.